- Home
- MKTX vs NUVL Comparison
MKTX vs NUVL Comparison
Compare MKTX & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTX
- NUVL
- Stock Information
- Founded
- MKTX 2000
- NUVL 2017
- Country
- MKTX United States
- NUVL United States
- Employees
- MKTX N/A
- NUVL N/A
- Industry
- MKTX Investment Bankers/Brokers/Service
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- MKTX Finance
- NUVL Health Care
- Exchange
- MKTX Nasdaq
- NUVL Nasdaq
- Market Cap
- MKTX 6.4B
- NUVL 7.2B
- IPO Year
- MKTX 2004
- NUVL 2021
- Fundamental
- Price
- MKTX $161.58
- NUVL $91.03
- Analyst Decision
- MKTX Buy
- NUVL Strong Buy
- Analyst Count
- MKTX 11
- NUVL 12
- Target Price
- MKTX $223.55
- NUVL $123.33
- AVG Volume (30 Days)
- MKTX 574.8K
- NUVL 576.9K
- Earning Date
- MKTX 11-07-2025
- NUVL 10-30-2025
- Dividend Yield
- MKTX 1.89%
- NUVL N/A
- EPS Growth
- MKTX N/A
- NUVL N/A
- EPS
- MKTX 5.95
- NUVL N/A
- Revenue
- MKTX $837,157,000.00
- NUVL N/A
- Revenue This Year
- MKTX $6.46
- NUVL N/A
- Revenue Next Year
- MKTX $8.66
- NUVL N/A
- P/E Ratio
- MKTX $27.02
- NUVL N/A
- Revenue Growth
- MKTX 7.67
- NUVL N/A
- 52 Week Low
- MKTX $156.17
- NUVL $55.54
- 52 Week High
- MKTX $290.69
- NUVL $104.90
- Technical
- Relative Strength Index (RSI)
- MKTX 35.67
- NUVL 49.80
- Support Level
- MKTX $156.17
- NUVL $90.00
- Resistance Level
- MKTX $161.80
- NUVL $104.90
- Average True Range (ATR)
- MKTX 3.53
- NUVL 5.10
- MACD
- MKTX -0.35
- NUVL -0.88
- Stochastic Oscillator
- MKTX 32.70
- NUVL 14.67
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.